# A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

Source: https://onco.cc/trials/nct06660654/  
OnCo record `nct06660654` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Raludotatug deruxtecan in advanced solid tumours, run by Daiichi Sankyo, active and no longer recruiting.

## Summary

A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) is a phase 2 interventional study registered as NCT06660654 by Daiichi Sankyo, with 200 participants enrolled, started 2025-01-06 and due to reach its primary completion in 2027-09-30. Interventions recorded: Raludotatug deruxtecan.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06660654
- Phase: 2
- Setting: REJOICE-PanTumor01: A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants With Advanced/Metastatic Solid Tumors
- Sponsor: Daiichi Sankyo
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT06660654: https://clinicaltrials.gov/study/NCT06660654

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Raludotatug deruxtecan](https://onco.cc/drugs/raludotatug-deruxtecan/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06660654.json